Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
8.27
+0.03 (0.36%)
Sep 18, 2024, 4:00 PM EDT - Market closed

Company Description

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe.

It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).

The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.

It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Theravance Biopharma, Inc.
Theravance Biopharma logo
Country United States
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 99
CEO Rick Winningham

Contact Details

Address:
901 Gateway Boulevard
South San Francisco, California 94080
United States
Phone 650 808 6000
Website theravance.com

Stock Details

Ticker Symbol TBPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001583107
CUSIP Number G8807B106
ISIN Number KYG8807B1068
SIC Code 2834

Key Executives

Name Position
Rick E. Winningham M.B.A. Chairman and Chief Executive Officer
Aziz Sawaf C.F.A. Senior Vice President and Chief Financial Officer
Stuart Knight Senior Vice President of IT&I and Chief Information Officer
Gail B. Cohen Vice President of Corporate Communications and Investor Relations
Brett A. Grimaud Esq. Senior Vice President, General Counsel and Secretary
Rhonda F. Farnum Chief Business Officer and Senior Vice President of Commercial and Medical Affairs
Stacy L. Pryce Senior Vice President and Chief Strategy Officer
Dr. Aine Miller Ph.D. SVice President of Dev., VP of Regu., Quality, Clinical Safety and Pharmacovigilance and Head of Ireland Office

Latest SEC Filings

Date Type Title
Sep 10, 2024 8-K Current Report
Sep 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 16, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 8, 2024 10-Q Quarterly Report
Aug 5, 2024 8-K Current Report
Jun 11, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
May 15, 2024 10-Q Quarterly Report
May 13, 2024 8-K Current Report
May 9, 2024 8-K Current Report